Munich - Delayed Quote EUR

Biofrontera Inc. (AI10.MU)

Compare

0.7950

0.0000

(0.00%)

At close: October 31 at 3:18:53 PM GMT+1

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for AI10.MU

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biofrontera Inc. (AI10.MU)

Comparisons

Indicators

Technicals

Corporate Events

0.00%

0.00%

6.00%

-18.46%

0.00%

-60.64%

-98.03%

-98.03%

Recent News: AI10.MU

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)